SLASAs artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
EBD Group/InformaJoin us for the 2nd BIO-Europe in Cologne, Germany, November 9–11, 2026, the premier biopharma partnering event now transformed into a comprehensive forum for biotech leaders.
ELRIGDrug discovery depends on more than breakthrough science alone. Progress increasingly emerges from connected ecosystems where academia, biotech, pharma, CROs and technology providers can openly exchange ideas, challenge assumptions and accelerate innovation together.
With the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the source of novel targets. To advance the already pre-validated selection more quickly, the company is now looking for partners. The response has been strong, say Matthias Evers and Hartmut Juhl in conversation with European Biotechnology Magazine.
Andre DallavalleSee-and-Treat Concept using Radioactive Smart Probes: Professor Rudolf Werner provides an overview of established and future indications in clinical practice, highlighting advances in theranostics and their growing impact on precision oncology.
CM4Cure. All Rights Reserved.CM4Cure is focused on substantially improving patient outcomes, improving medical device performance by incorporating drug delivery. Our technology redefines medical device coatings – converting passive barriers into active systems via a unique nanogel able to deliver multiple APIs. Initially focused on iv catheters – >2bn are used globally pa – the platform has potential to reduce infection and thrombosis across a swathe of medical devices
SecarnaSecarna Pharmaceuticals is redefining the discovery and development of oligonucleotide therapeutics to address hard-to-treat disorders. The Company is planning to raise a Series A to advance its lead oncology asset, SECN-15, into Phase 1/2. Secarna is supported by global partnerships that validate their expertise and accelerate development.
3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner for the development and manufacturing of recombinant proteins.
Chemspec EuropeChemspec Europe returned to Cologne between 6-7 May 2026, drawing 4,238 attendees from 60 nations and 454 exhibitors from 28 countries, an increase from last year’s event.